Two randomized trials in China find that intra-arterial thrombolysis with urokinase or tenecteplase does not significantly improve functional recovery after successful EVT in patients with stroke.

Intra-arterial thrombolysis via urokinase following reperfusion by endovascular thrombectomy for stroke does not affect survival without disability.

It estimated that 20% of stroke patients could benefit from thrombolysis, a drug that breaks down a clot and returns blood supply to the brain, which should be administered within four and a half ...

Recombinant human prourokinase is noninferior to alteplase in acute ischemic stroke, with symptomatic intracranial hemorrhage and major bleeding decreased.

A new meta-analysis examines the effects of dual antiplatelet therapy after thrombolysis in minor stroke patients. Findings ...

Tenecteplase provides comparable safety and effectiveness outcomes for acute ischemic stroke as alteplase, new research ...

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window The FDA ...

For patients with ischemic stroke, tenecteplase seems to be a reasonable alternative to alteplase in terms of effectiveness and safety outcomes.

Clinuvel Pharmaceuticals (ASX:CUV) has reported encouraging preliminary results from its second study of afamelanotide in ...

Aster MIMS Kozhikode has achieved Comprehensive Stroke Center accreditation from the American Heart Association (AHA). The ...

The FDA approved tenecteplase (TNKase) for adult stroke patients, Genentech announced on Monday. A clot-dissolving tissue plasminogen activator (tPA), tenecteplase is now indicated for acute ...